Related Experiment Video
Updated: Jun 3, 2026
13:04
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Carcinosarcoma of the ovary: a case-control study
J Alejandro Rauh-Hain1, Whitfield B Growdon, Noah Rodriguez
1Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Gynecologic Oncology
|March 23, 2011
Summary
Patients with advanced ovarian carcinosarcoma show poorer chemotherapy response and survival compared to epithelial ovarian cancer. New treatments are needed for this rare ovarian cancer.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Pathology
Background:
- Ovarian carcinosarcoma is a rare malignancy with a poor prognosis.
- Current chemotherapy regimens are based on epithelial ovarian cancer (EOC) guidelines.
- Limited data exists comparing treatment response and survival for advanced ovarian carcinosarcoma.
Purpose of the Study:
- To compare chemotherapy response rates in patients with advanced ovarian carcinosarcoma versus serous EOC.
- To evaluate and compare survival outcomes (progression-free and overall survival) between these two groups.
- To identify factors influencing outcomes in advanced ovarian carcinosarcoma.
Main Methods:
- Retrospective matched cohort study.
- Fifty patients with advanced ovarian carcinosarcoma (cases) were matched with two patients with serous EOC (controls) by age, stage, and diagnosis year.
- Kaplan-Meier method for survival analysis; log-rank test and Cox proportional hazards model for outcome predictors.
Main Results:
- Chemotherapy response rates were significantly lower in carcinosarcoma patients (62%) compared to EOC patients (83%) (P=0.03).
- Median progression-free survival was shorter for carcinosarcoma (11 months) versus EOC (16 months) (P=0.02).
- Median overall survival was significantly worse for carcinosarcoma patients (24 months) compared to EOC patients (41 months) (P=0.002).
Conclusions:
- Advanced ovarian carcinosarcoma patients experience inferior response to platinum and taxane chemotherapy and reduced survival compared to serous EOC.
- The findings suggest a need for novel systemic therapeutic strategies for ovarian carcinosarcoma.
- Aggressive surgical management may be beneficial, but alternative treatments are warranted.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...